Enter your keywords

NICE TA875; Semaglutide for managing obesity: A briefing for ICSs  

In March 2023 NICE published TA875: Technology Appraisal guidance for semaglutide (Wegovy®) for managing overweight and obesity. The guidance recommends semaglutide as an option for weight management when prescribed by a specialist service alongside a reduced-calorie diet and increased physical activity in adults if they meet the criteria specified. This briefing aims to provide advice […]

Problematic Polypharmacy:  Prescribing Cascades Evidence Evaluation

Problematic polypharmacy is a significant concern with overprescribing and occurs where the prescribing of multiple medicines is either inappropriate or where the intended benefit of the medication is not realised. Prescribing cascades contribute to problematic polypharmacy because they can lead to inappropriate medication use, adverse drug reactions, poor outcomes and increased healthcare resource use that […]

Polypharmacy & Overprescribing: Opioid population health management

In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing: Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of […]

Polypharmacy & Overprescribing: Opioid patient demographics

In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing: Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of […]

Polypharmacy & Overprescribing: Opioid patient populations

In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing: Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of […]

Budget impact of metformin 1g immediate release tablet prescribing

The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g […]

North of England Integrated Care Systems; Overprescribing

This bulletin provides an update on key primary care prescribing trends in the North of England, which relate to ‘Overprescribing’; incorporating ‘Polypharmacy’. It provides a snapshot of overprescribing in the North of England Integrated Care Systems, including the percentage of patients receiving five or more unique analgesic medicines, and those receiving three unique medicines (not […]

Reducing the carbon impact of inhalers across the North of England

This bulletin provides baseline figures on the current Inhaler Carbon Footprint at ICS level in the North of England, in order that systems can identify the level of response to be undertaken. It examines the current carbon footprint attributed to Inhalers in the North East and Yorkshire and the North West. It also analyses the […]